Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome

Thrombosis Research

Volumn 124, Issue 5, 2009, Pages 614-618

  Tàssies, Dolors ^a   Roqué, Merce ^a   Monteagudo, Joan ^a   Martorell, Teresa ^a   Sionis, Alessandro ^a   Arzamendi, Dabit ^a   Heras, Magda ^a   Reverter, Joan Carles ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Acute coronary syndrome; Fibrinolysis; PAI 1; Polymorphism; TAFI

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLYCERYL TRINITRATE; INSULIN; MORPHINE; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; DYSLIPIDEMIA; FEMALE; FIBRINOLYSIS; GENE FREQUENCY; GENETIC ASSOCIATION; GENOME ANALYSIS; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; Q WAVE; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; CARBOXYPEPTIDASE U; COHORT STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 70349856157     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.07.004     Document Type: Article

References (33)

1. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
2. Hamsten A., Wiman B., de Faire U., and Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor in young survivors of myocardial infarction. N Eng J Med 313 (1985) 1557-1563
3. Undas A., Szuldrzynski K., Stepien E., Zalewski J., Godlewski J., Tracz W., et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 196 (2008) 551-557
4. Itakura H., Sobel B.E., Boothroyd D., Leung L.L., Iribarren C., Go A.S., et al. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?. Am Heart J 154 (2007) 1059-1064
5. Silveira A., Schatteman K., Goossens F., Moor E., Scharpé S., Strömqvist M., et al. Plasma procarboxipeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84 (2000) 364-368
6. Brouwers G.J., Leebeek F.W., Tanck M.W., Jukema J.W., Kluft C., and de Maat MP. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 90 (2003) 92-100
7. Dawson S., Hamsten A., Wiman B., Henney A., and Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11 (1991) 183-190
8. Zhao L., Morser J., Bajzar L., Nesheim M., and Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 80 (1998) 949-955
9. Brouwers G.J., Vos H.L., Leebeek F.W., Bulk S., Schneider M., Boffa M., et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 98 (2001) 1992-1993
10. Henry M., Aubert H., Morange P.E., Nanni I., Alessi M.C., Tiret L., et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97 (2001) 2053-2058
11. Gils A., Alessi M.C., Browers E., Peeters M., Marx P., Leurs J., et al. Development of a genotipe 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 23 (2003) 1122-1127
12. Lisman T., Leebek F.W., Mosnier L.O., Bouma B.N., Meijers J.C., Janssen H.L., et al. Thrombin activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121 (2001) 131-139
13. Tàssies D., Espinosa G., Muñoz-Rodriguez F.J., Freire C., Cervera R., Monteagudo J., et al. The 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene and thrombosis in patients with the antiphospholipid syndrome. Arthritis Rheum 43 (2000) 2349-2358
14. Ardlie K.G., Kruglyak L., and Seielstad M. Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 3 (2002) 299-309
15. Woolf B. On estimating the relation between blood group and disease. Ann Human Genet 19 (1955) 251-253
16. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 (1995) 657-671
17. Rauch U., Osende J.I., Fuster V., Badimon J.J., Fayad Z., and Chesebro J.H. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 134 (2001) 224-238
18. Juhan-Vague I., Morange P.E., Aubert H., Henry M., Aillaud M.F., Alessi M.C., et al. Plasma Thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22 (2002) 867-873
19. Santamaría A., Martínez-Rubio A., Borrell M., Mateo J., Ortín R., and Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 89 (2004) 880-881
20. Morange P.E., Juhan-Vague I., Scarabin P.Y., Alessi M.C., Luc G., Arveiler D., et al. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI). Thromb Haemost 89 (2003) 554-560
21. Folkeringa N., Coppens M., Veeger N.J., Bom V.J., Middeldorp S., Hamulyak K., et al. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost 100 (2008) 38-44
22. Cellai A.P., Antonucci E., Liotta A.A., Fedi S., Marcucci R., Falciani M., et al. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 118 (2006) 495-500
23. Guimarães A.H.C., van Tilburg N.H., Vos H.L., Bertina R.M., and Rijken D.C. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 124 (2004) 659-665
24. Morange P.E., Tregouet D.A., Frere C., Luc G., Arveiler D., Ferrieres J., et al. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME study. J Thromb Haemost 3 (2005) 1503-1510
25. Schneider M., Boffa M., Stewart R., Rahman M., Koschinsky M., and Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 277 (2002) 1021-1030
26. Boffa M.B., and Koschinsky M.L. Curiouser and curiouser: Recent advances in measurement of thrombin activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 40 (2007) 431-442
27. Lau H.K., Segev A., Hegele R.A., Sparkes J.D., Teitel J.M., Chisholm R.J., et al. Thrombin activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thromb Haemost 90 (2003) 1187-1191
28. Segev A., Hegele R.A., Lau H.K., Sparkes J.D., Teitel J.M., Chisholm R.J., et al. Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions. Thromb Res 114 (2004) 137-141
29. Tregouet D.A., Schnabel R., Alessi M.C., Godefroy T., Declerck P.J., Nicaud V., et al. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 7 (2009) 49-57
30. Morange P.E., Saut N., Alessi M.C., Yudkin J.S., Margaglione M., Di Minno G., et al. Association of plasminogen activator inhibitor (PAI)-1 (serpine1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters. The HIFMECH study. Arterioscler Thromb Vasc Biol 27 (2007) 2250-2257
31. Onalan O., Balta G., Oto A., Kabakci G., Tokgozoglu L., Aytemir K., et al. Plasminogen activator inhibitor-1 4G/4G genotype is associated with myocardial infarction but not with stable coronary artery disease. J Thromb Thrombolysis 26 (2008) 211-217
32. Tsantes A.E., Nikolopoulos G.K., Bagos P.G., Rapti E., Mantzios G., Kapsimali V., et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 97 (2007) 907-913
33. Pons D., Monraats P.S., de Maat M.P., Pires N.M., Quax P.H., van Vlijmen B.J., et al. The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. Thromb Haemost 98 (2007) 1323-1328